Literature DB >> 7820541

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

R A Luqmani1, P A Bacon, R J Moots, B A Janssen, A Pall, P Emery, C Savage, D Adu.   

Abstract

The continuing morbidity of patients with vasculitis, despite the improved prognosis with aggressive therapy, underlines the need for accurate disease assessment. We have devised a clinical index of disease activity, and evaluated its use in several forms of necrotizing vasculitis. The weighted score is based on symptoms and signs in nine separate organ systems. Disease features are only scored if they are attributable to active vasculitis. The Birmingham Vasculitis Activity Score (BVAS) was compared with two other published vasculitis activity scores, with the physician's global assessment (PGA), with outcome, and with serological markers of disease activity. In a cross-sectional study of 213 consecutive patients with different forms of vasculitis, all 107 vasculitis patients who were judged completely well on clinical assessment had a BVAS score of 0. Twenty-two patients with active vasculitis prior to treatment had a median score of 7.5 (range 4-30) and 69 with active disease on treatment had a median score of 10 (1-29). Of the 12 who died, median score immediately prior to death was 20.5 (9-30). In a serial prospective study, 30 cases had documented episodes of active disease. During periods of disease activity, the median BVAS values were significantly higher than in remission (15 [range 3-32] vs. 0 [0-2], p < 0.001); the same was true for CRP values (80 [9-361] vs. 13.5 [5-68], p < 0.001). This was not true for erythrocyte sedimentation rate (ESR), haemoglobin (Hb) or von Willebrand factor (VWF).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7820541

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  274 in total

1.  Monocyte activation in patients with Wegener's granulomatosis.

Authors:  A C Muller Kobold; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

Review 2.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Elevated monocytic IL-12 and TNF-alpha production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy.

Authors:  P Lamprecht; G Kumanovics; A Mueller; E Csernok; A Komocsi; A Trabandt; W L Gross; A Schnabel
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.

Authors:  M M Boomsma; D J Stearns-Kurosawa; C A Stegeman; E Raschi; P L Meroni; S Kurosawa; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

5.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis.

Authors:  Andras Komocsi; Peter Lamprecht; Elena Csernok; Antje Mueller; Konstanze Holl-Ulrich; Ulrike Seitzer; Frank Moosig; Armin Schnabel; Wolfgang Ludwig Gross
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 6.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

7.  A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature.

Authors:  S F Sørensen; O Slot; N Tvede; J Petersen
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

8.  A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.

Authors:  Michael C Sneller; Zonghui Hu; Carol A Langford
Journal:  Arthritis Rheum       Date:  2012-03

9.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Authors:  Antoine G Sreih; Fatma Alibaz-Oner; Tanaz A Kermani; Sibel Z Aydin; Peter F Cronholm; Trocon Davis; Ebony Easley; Ahmet Gul; Alfred Mahr; Carol A McAlear; Nataliya Milman; Joanna C Robson; Gunnar Tomasson; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

10.  Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise.

Authors:  Sibel Z Aydin; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.